JingJing Wei

Dr. JingJing Wei

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
ZZZeHao Zhuang
ZeHao Zhuang
JXJing-Jing Xie
Jing-Jing Xie
JWJingJing Wei
JingJing Wei
DTDu-Peng Tang
Du-Peng Tang
LYLi-Yong Yang
Li-Yong Yang
Background: Polyunsaturated fatty acids (PUFAs) play various roles in inflammation. However, the effect of PUFAs in the development of reflux esophagitis (RE) is unclear. This study is to investigate the potential effect of n-3/n-6 PUFAs on acute RE in rats along with the underlying protective mechanisms. Methods: Forty Sprague Dawley rats were randomly divided into four groups (n = 10 in each group). RE model was established by pyloric clip and section ligation. Fish oil- and soybean oil-based fatty emulsion (n-3 and n-6 groups), or normal saline (control and sham operation groups) was injected intraperitoneally 2 h prior to surgery and 24 h postoperatively (2 mL/kg, respectively). The expressions of interleukin (IL)-1β, IL-8, IL-6 and myeloid differentiation primary response gene 88 (MyD88) in esophageal tissues were evaluated by Western blot and immunohistochemistry after 72 h. The malondialdehyde (MDA) and superoxide dismutase (SOD) expression in the esophageal tissues were determined to assess the oxidative stress. Results: The mildest macroscopic/microscopic esophagitis was found in the n-3 group (P < 0.05). The expression of IL-1β, IL-8, IL-6 and MyD88 were increased in all RE groups, while the lowest and highest expression were found in n-3 and n-6 group, respectively (P < 0.05). The MDA levels were increased in all groups (P < 0.05), in an ascending trend from n-3, n-6 groups to control group. The lowest and highest SOD levels were found in the control and n-3 group, respectively (P < 0.05). Conclusion: n-3 PUFAs may reduce acute RE in rats, which may be due to inhibition of the MyD88-NF-kB pathway and limit oxidative damage.

12 April 2025 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
NYNaoyuki Yamaguchi
Naoyuki Yamaguchi
JWJingJing Wei
JingJing Wei
HIHajime Isomoto
Hajime Isomoto
Effective therapeutic strategies for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remain challenging, including a lack of response to therapy and post-treatment relapse. The rapid development of targeted radionuclide therapy (TRT) offers promising data for patients with somatostatin receptor (SSTR)-expressing tumors. This approach exhibits more advantages than somatostatin analog (SSA) therapy, which is primarily effective for well-differentiated and slow-growing GEP-NENs. Fortunately, some clinical studies on peptide receptor radionuclide therapy (PRRT) labeled with α-emitting radionuclides for GEP-NENs patients showed effective results for those with more advanced GEP-NENs, or those with malignant metastasis. For the improvement of clinical efficacy and the decline in the incidence of treatment-related relapse, recent progress in developing novel techniques and effective disease management strategies for optimal targeting has led to the emergence of targeted alpha therapy (TAT) in GEP-NENs patients. For instance, labeled technology and combination therapy could contribute to significantly improved long-term outcomes. However, the exact dosimetry for precision oncology, the shortage of radionuclides, and the stability of disease control are still under careful consideration. More high-quality, large-scale prospective studies are essential for obtaining valuable evidence on challenging problems and for further exploration. Graphical abstract

16 August 2016 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
PDF file
JWJingJing Wei
JingJing Wei
DTDu-Peng Tang
Du-Peng Tang
JXJing-Jing Xie
Jing-Jing Xie
LYLi-Yong Yang
Li-Yong Yang
ZZZeHao Zhuang
ZeHao Zhuang

17 June 2024 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
WYWei-Jia You
Wei-Jia You
TLTing-Ting Lian
Ting-Ting Lian
OQOu Qian
Ou Qian
JWJingJing Wei
JingJing Wei
ZZZeHao Zhuang
ZeHao Zhuang

8 September 2025 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
WLWei Lin
Wei Lin
YLYi-Zhi Liang
Yi-Zhi Liang
DPDun-Huang Peng
Dun-Huang Peng
JWJun-Xi Wang
Jun-Xi Wang
SHSi-Fu Huang
Si-Fu Huang
ZZZeHao Zhuang
ZeHao Zhuang

10 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
JWJingJing Wei
JingJing Wei
HKHiroki Kurumi
Hiroki Kurumi
Hajime IsomotoHajime Isomoto
Hajime Isomoto
RORyohei Ogihara
Ryohei Ogihara
KMKayoko Matsushima
Kayoko Matsushima
KTKazuhiro Tsukamoto
Kazuhiro Tsukamoto
Objectives: To explore the possible relationship between Toll-like receptor (TLR) gene encoding and a predictive outcome for the loss of response (LOR) to IFX treatment among Japanese patients with Crohn’s disease (CD). Methods: An association analysis that involved 25 single-nucleotide polymorphisms (SNPs) across the TLR1, TLR2, TLR4, TLR6, TLR9, and TLR10 genes was performed on a cohort of 127 Japanese patients with CD. The therapeutic responses were evaluated at 10 weeks, 1 year, and 2 years using three different inheritance models. Results: The CD patients with a G/G genotype of rs5743565 in TLR1 were significantly less likely in the responders at 10 weeks compared with the non-responders (p = 0.023, OR = 0.206). The frequencies of the C/T or T/T genotypes of rs5743604 in the TLR1, G/A, or A/A genotypes of rs13105517 in TLR2, both in the minor allele dominant model, were significantly higher in the responders at 10 weeks as compared with those in the non-responders (p = 0.035, OR = 4.401; p = 0.017, OR = 5.473). The patients with an A/A genotype of rs13105517 in TLR2 in the minor allele recessive model were significantly less likely in the responders at one year of IFX treatment compared with those in the non-responders (p = 0.004, OR = 0.195). Conclusions: The polymorphisms of TLR1 and TLR2 can be useful as biomarkers for predicting initial and secondary LOR to IFX in Japanese CD patients. The IFX response in genetic testing may target molecules for new drugs to overcome the non-response and LOR to IFX.